Sabby Management’s InMed Pharmaceuticals INM Stock Holding History

Sabby Management’s Portfolio INM Stock Details INM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$69.7K	Sell	44,970 -175,290	-80%	-$194K	0.06%	21
2026 Q1	$142K	Buy	220,260 +18,627	+9%	+$17.6K	0.32%	19
2025 Q4	$214K	Sell	201,633 -18,365	-8%	-$30.5K	0.31%	23
2025 Q3	$482K	Buy	+219,998	New	+$530K	0.56%	16
2024 Q3	–	Sell	-15,362	Closed	-$81.6K	–	53
2024 Q2	$81.6K	Sell	15,362 -2,724	-15%	-$15.6K	0.05%	29
2024 Q1	$132K	Sell	18,086 -7,511	-29%	-$55.2K	0.08%	28
2023 Q4	$213K	Buy	+25,597	New	+$248K	0.21%	22
2022 Q4	–	Sell	-764	Closed	-$101K	–	118
2022 Q3	$101K	Buy	+764	New	+$141K	0.13%	80

Other funds holding INM

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

UFM

Ursa Fund Management Danville, California $1.28B AUM 89.08% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Sabby Management's INM Position: Q2 2026 in Review

Sabby Management reduced its InMed Pharmaceuticals (INM) stake by 80% in Q2 2026, selling an estimated $194K and leaving 44,970 shares worth $69.7K. The position accounts for 0.06% of the portfolio, ranked #21.

Sabby Management first reported a position in INM in Q3 2022 and has held it in 8 quarters since. The position peaked at $482K in Q3 2025. 20 funds tracked by Wall St. Rank hold INM as of Q2 2026.

Sabby Management held 44,970 shares of InMed Pharmaceuticals worth $69.7K as of Q2 2026.
Sabby Management sold 175,290 InMed Pharmaceuticals shares in Q2 2026, an estimated $194K.
InMed Pharmaceuticals made up 0.06% of Sabby Management's portfolio in Q2 2026, its #21 holding.
Sabby Management first reported a position in InMed Pharmaceuticals in Q3 2022 and has held it in 8 quarters since.
Sabby Management's InMed Pharmaceuticals position peaked at $482K in Q3 2025.
20 funds tracked by Wall St. Rank held InMed Pharmaceuticals as of Q2 2026.

Based on Sabby Management's 13F filing for Q2 2026, filed 14 Aug 2026.